REUTLINGEN, Germany--(BUSINESS WIRE)--Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during the company’s first human clinical trial. The results achieved in the 11 patients that were involved in the trial exceeded the company’s expectations for their first trial. In fact, a few of the patients were able to see objects and shapes so clearly they could combine letters to form words and recognize foreign objects. Previous studies conducted by other companies’ also developing retinal implants have found their technology facilitated the ability to see light and outlines of objects, but did not produce a level of sight that enabled patients to read or recognize foreign objects. Retina Implant’s clinical trial began in Germany in 2005 and has involved 11 patients who lost their sight due to retinitis pigmentosa (RP).
